Cargando…

Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation

Rifaximin, a non-absorbable antibiotic, has been demonstrated to be effective against hepatic encephalopathy (HE); however, its efficacy on liver functional reserve remains unknown. Here, we evaluated the efficacy of rifaximin on the liver functional reserve and serological inflammation-based marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitsugi, Kensuke, Kawata, Kazuhito, Noritake, Hidenao, Chida, Takeshi, Ohta, Kazuyoshi, Ito, Jun, Takatori, Shingo, Yamashita, Maho, Hanaoka, Tomohiko, Umemura, Masahiro, Matsumoto, Moe, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054398/
https://www.ncbi.nlm.nih.gov/pubmed/36983211
http://dx.doi.org/10.3390/jcm12062210
_version_ 1785015661181796352
author Kitsugi, Kensuke
Kawata, Kazuhito
Noritake, Hidenao
Chida, Takeshi
Ohta, Kazuyoshi
Ito, Jun
Takatori, Shingo
Yamashita, Maho
Hanaoka, Tomohiko
Umemura, Masahiro
Matsumoto, Moe
Suda, Takafumi
author_facet Kitsugi, Kensuke
Kawata, Kazuhito
Noritake, Hidenao
Chida, Takeshi
Ohta, Kazuyoshi
Ito, Jun
Takatori, Shingo
Yamashita, Maho
Hanaoka, Tomohiko
Umemura, Masahiro
Matsumoto, Moe
Suda, Takafumi
author_sort Kitsugi, Kensuke
collection PubMed
description Rifaximin, a non-absorbable antibiotic, has been demonstrated to be effective against hepatic encephalopathy (HE); however, its efficacy on liver functional reserve remains unknown. Here, we evaluated the efficacy of rifaximin on the liver functional reserve and serological inflammation-based markers in patients with cirrhosis. A retrospective study was conducted on patients who received rifaximin for more than three months at our hospital between November 2016 and October 2021. The recurrence and grade of HE, serological ammonia levels, Child–Pugh score (CPS), and serological inflammation-based markers such as the neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), platelet–lymphocyte ratio (PLR), C-reactive protein (CRP), and CRP to albumin ratio (CAR) were evaluated. The correlations between serological inflammation-based markers and liver functional reserve were evaluated. HE grades, serum ammonia levels, and inflammation-based markers significantly improved at three months compared with those at baseline. Patients with improved albumin levels showed significantly higher CRP improvement rates at both 3 and 12 months. Patients with an improvement in CAR at 3 months demonstrated a significant improvement in CPS at 12 months. Rifaximin improved the liver functional reserve in patients with cirrhosis. Improvements in inflammation-based markers, particularly CRP and albumin, may be involved in this process.
format Online
Article
Text
id pubmed-10054398
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100543982023-03-30 Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation Kitsugi, Kensuke Kawata, Kazuhito Noritake, Hidenao Chida, Takeshi Ohta, Kazuyoshi Ito, Jun Takatori, Shingo Yamashita, Maho Hanaoka, Tomohiko Umemura, Masahiro Matsumoto, Moe Suda, Takafumi J Clin Med Article Rifaximin, a non-absorbable antibiotic, has been demonstrated to be effective against hepatic encephalopathy (HE); however, its efficacy on liver functional reserve remains unknown. Here, we evaluated the efficacy of rifaximin on the liver functional reserve and serological inflammation-based markers in patients with cirrhosis. A retrospective study was conducted on patients who received rifaximin for more than three months at our hospital between November 2016 and October 2021. The recurrence and grade of HE, serological ammonia levels, Child–Pugh score (CPS), and serological inflammation-based markers such as the neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), platelet–lymphocyte ratio (PLR), C-reactive protein (CRP), and CRP to albumin ratio (CAR) were evaluated. The correlations between serological inflammation-based markers and liver functional reserve were evaluated. HE grades, serum ammonia levels, and inflammation-based markers significantly improved at three months compared with those at baseline. Patients with improved albumin levels showed significantly higher CRP improvement rates at both 3 and 12 months. Patients with an improvement in CAR at 3 months demonstrated a significant improvement in CPS at 12 months. Rifaximin improved the liver functional reserve in patients with cirrhosis. Improvements in inflammation-based markers, particularly CRP and albumin, may be involved in this process. MDPI 2023-03-13 /pmc/articles/PMC10054398/ /pubmed/36983211 http://dx.doi.org/10.3390/jcm12062210 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kitsugi, Kensuke
Kawata, Kazuhito
Noritake, Hidenao
Chida, Takeshi
Ohta, Kazuyoshi
Ito, Jun
Takatori, Shingo
Yamashita, Maho
Hanaoka, Tomohiko
Umemura, Masahiro
Matsumoto, Moe
Suda, Takafumi
Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
title Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
title_full Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
title_fullStr Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
title_full_unstemmed Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
title_short Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation
title_sort rifaximin improves liver functional reserve by regulating systemic inflammation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054398/
https://www.ncbi.nlm.nih.gov/pubmed/36983211
http://dx.doi.org/10.3390/jcm12062210
work_keys_str_mv AT kitsugikensuke rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT kawatakazuhito rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT noritakehidenao rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT chidatakeshi rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT ohtakazuyoshi rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT itojun rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT takatorishingo rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT yamashitamaho rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT hanaokatomohiko rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT umemuramasahiro rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT matsumotomoe rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation
AT sudatakafumi rifaximinimprovesliverfunctionalreservebyregulatingsystemicinflammation